Prosecution Insights
Last updated: October 04, 2026

Adaptive Phage Therapeutics LLC

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Adaptive Phage Therapeutics LLC is currently focused on the Biotechnology & Pharmaceuticals technology area, where it has 1 pending office action. This action is being processed within 1 distinct art unit, indicating a concentrated technical scope for the company's current filings. The involvement of 1 distinct examiner, NGUYEN, PETER, means that the company's immediate prosecution path is managed by a single individual. This 1 busiest examiner pending office action represents the entirety of the company's active workload at the patent office.

For a practitioner, the concentration of 1 pending office action under 1 distinct examiner in 1 distinct art unit requires a highly specific strategy. The outcome of the company's current efforts in the Biotechnology & Pharmaceuticals sector depends entirely on the review by NGUYEN, PETER. While this ratio of actions to examiners simplifies the administrative tracking of the portfolio, it also focuses all prosecution risk on a single point of review. The reliance on 1 distinct art unit suggests that Adaptive Phage Therapeutics LLC is pursuing a very specific technical objective within its current patent application.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
NGUYEN, PETER 1 — —

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18454156 COMPUTER IMPLEMENTED METHOD FOR ANALYZING HOST PHAGE RESPONSE DATA NGUYEN, PETER —

Top Art Units

Art UnitApps
1645 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18454156 COMPUTER IMPLEMENTED METHOD FOR ANALYZING HOST PHAGE RESPONSE DATA NGUYEN, PETER 1645 §101§103 Non-Final OA — Pending Aug 23, 2023

Managing Adaptive Phage Therapeutics LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month